Fanconi anemia complementation group A
MONDO:0009215Fanconi anemia caused by mutations of the FANCA gene. FANCA gene mutations are the most common cause of Fanconi anemia. This gene provides instructions for making a protein that is involved in the Fanconi anemia (FA) pathway.
Also known as: FANCA, FANCA Fanconi anaemia, FANCA Fanconi anemia, Fanconi Anemia, complementation group type a, Fanconi anaemia caused by mutation in FANCA, Fanconi anaemia complementation group type A, Fanconi anemia caused by mutation in FANCA, Fanconi anemia complementation group A
16 clinical trials for this condition and its sub-types, 4 tagged with Fanconi anemia complementation group A itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →-
Gene therapy for rare blood disease passes 15-Year safety watch
Disease control OngoingThis study follows 9 people with Fanconi Anemia who already received a gene therapy that adds a working FANCA gene to their blood stem cells. Researchers will check their health and blood counts for 15 years to see if the treatment remains safe and keeps working. No new treatment…
Sponsor: Rocket Pharmaceuticals Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
Experimental gene therapy aims to stop bone marrow failure in kids with rare disease
Disease control OngoingThis phase 2 trial tests a gene therapy called RP-L102 for children with Fanconi anemia subtype A, a rare genetic disorder that leads to bone marrow failure. Doctors take the child's own blood stem cells, fix the faulty gene in a lab, and infuse the corrected cells back. The goal…
Phase 2 • Sponsor: Rocket Pharmaceuticals Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:06 UTC